ORG 34517

Drug Profile

ORG 34517

Alternative Names: ORG-34517; SCH-900636

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Organon
  • Developer Merck & Co; Organon; Pop Test
  • Class Antidepressants; Antineoplastics; Benzodioxoles; Chemosensitisers; Diagnostic agents; Phenanthrenes; Steroids
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Breast cancer
  • Discontinued Major depressive disorder

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral, Injection)
  • 25 Oct 2011 ORG 34517 is available for licensing as of 25 Oct 2011.
  • 25 Oct 2011 Pop Test acquires ORG 34517 from Merck & Co.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top